The IL3 Knockout NCI-H1703 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population derived from the human non-small cell lung cancer epithelial cell line NCI-H1703, featuring targeted disruption of the IL3 gene. This product provides a heterogeneous pool of knockout cells, avoiding clonal selection biases and enabling robust functional studies of interleukin-3 signaling in a lung squamous cell carcinoma background. The polyclonal format is especially suited for experiments where population-level responses are critical, such as proliferation assays, signaling analyses, and tumor microenvironment modeling.
The host cell line, NCI-H1703, is a well-characterized human lung squamous cell carcinoma model established from a patient with non-small cell lung cancer. These adherent epithelial cells retain key oncogenic features and are commonly employed to investigate lung cancer biology, including tumor?Cstroma interactions, cytokine networks, and drug responses. Their use in this knockout model provides a clinically relevant platform for examining the role of IL3 in solid tumors, where its autocrine and paracrine effects may diverge from its classical hematopoietic functions.
Interleukin-3, encoded by IL3, is a cytokine that signals through a heterodimeric receptor composed of IL3RA and CSF2RB. Ligand binding activates JAK2, which phosphorylates STAT5, leading to transcriptional regulation of downstream targets such as BCL2, CCND1, and MYC. Additionally, IL3 engagement stimulates the PI3K?CAKT and MAPK (ERK1/2) cascades, promoting cell survival and proliferation. Upstream regulators like NFAT, AP-1, and NF-??B induce IL3 expression upon T-cell receptor stimulation and calcium influx, while negative feedback is mediated by SOCS3. In the NCI-H1703 context, IL3 may act in an autocrine loop to modulate tumor cell biology.
Disruption of IL3 in NCI-H1703 cells eliminates this cytokine??s expression, thereby shutting down the IL3?CIL3RA?CCSF2RB?CJAK2?CSTAT5 signaling hub and its associated PI3K?CAKT and MAPK pathways. This loss-of-function model allows researchers to delineate the contribution of IL3 to squamous cell carcinoma proliferation, apoptosis resistance, and potential crosstalk with immune cells. Since lung cancer cells can produce and respond to IL3, the knockout provides a clean isogenic background to scrutinize pathway dependencies and identify context-specific mechanisms that differ from those in hematopoietic lineages.
Typical applications include Western blotting for phosphorylated STAT5 and ERK, RT-qPCR for downstream targets such as CCND1 and MYC, and functional assays like MTT or BrdU proliferation and Annexin V apoptosis measurements. The polyclonal knockout cells are also valuable for co-culture experiments mimicking the tumor microenvironment and for screening inhibitors targeting IL3 signaling. Moreover, they serve as controls for assessing off-target effects of IL3-directed therapies. For further information, please contact Ascent Research.
